Page 26 - Bharat Biotech

PM visits Bharat Biotech in Hyderabad to take stock of vaccine development

Modi visited drugmaker Zydus Cadila's plant near Ahmedabad earlier in the day.

Covid updates on vaccine, lockdown chances and PM's Serum institute visit

Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year of Russia's Covid vaccine Sputnik V, in India

PM Modi to visit Bharat Biotech's facility in Hyderabad on November 28

Prime Minister Narendra Modi is scheduled to visit vaccine maker Bharat Biotech's facility here on Saturday, the Telangana Chief Secretary Somesh Kumar said

Phase three trials of Bharat Biotech's covaxin commences in AIIMS

The trial will cover around 28,500 subjects aged 18 years and above

Covid vaccine: Bharat Biotech's Covaxin reach Ahmedabad for phase-3 trials

The Sola civil hospital is one of the 130 centres across the country where the third phase of clinical trials of Covaxin would be conducted

Serum Institute, Bharat Biotech gear up to export Covid-19 vaccine shots

Serum, Bharat Biotech in talks with countries, agencies to supply vaccines

No impact of adverse event on Covid-19 vaccine timelines: Bharat Biotech

The firm said subject was now safe. Though it was reported to the drug regulator within 24 hours, the event turned out to be unrelated to the vaccine.

Bharat Biotech's coronavirus vaccine may be launched in February

Moderna and AstraZeneca are close behind the largest US drugmaker and are likely to have early data on their vaccine candidates before the end of the year.

Govt to prioritise Covid-19 vaccine for front line health workers: Report

The national vaccine distribution plan is being formulated with the assumption that limited volumes of the inoculation will be available in the first few months of production, Paul said

Cadila scouts partners to ramp up Covid vaccine production by 50 to 70 mn

The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its plasmid DNA vaccine

Covid vaccine updates: Key facts and major announcements you should know

All people of the country will be given Covid vaccine for free, Union Minister Pratap Sarangi announced on Sunday

Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Bharat Biotech in talks with over 10 nations to take Covid vaccine global

Read more at: https://www.deccanherald.com/business/indias-bharat-biotech-in-talks-to-take-vaccine-candidate-covaxin-global-906089.html

Bharat Biotech gets go-ahead to conduct Phase-III trials of Covaxin

The around 28,500 people expected to enrol for the Phase-III trials would be given two doses of the investigational vaccine

Covaxin: Bharat Biotech's Covid vaccine candidate gets Phase 3 trials nod

In a statement published on its website, the panel said it recommended granting the approval after studying the firm's Phase I and II data along with 'animal challenge data in two species'

Covid-19: Bharat Biotech cuts Covaxin phase-2 clinical trial size by half

For phase-2 studies, the firm is also testing the vaccine on children above 12 years of age. In phase-1, they only tested adults.

Indian samples of global Covid-19 vaccines need to be larger: Experts

Indian players like Bharat Biotech and Zydus Cadila ready for large-scale phase-3 trials

Inhaled vaccines aim to target coronavirus at its point of invasion

Most vaccines in human testing require two shots for effectiveness, and developers still aren't even sure if they'll prevent infections

Govt may allow use of Covid vaccine in emergency situations: Harsh Vardhan

Warns of spike in cases during winter; China, UAE among the few countries have allowed such authorisation

Bharat Biotech told to submit complete phase 2 data of its Covid-19 vaccine

Bharat Biotech, which had sought DCGI's nod for conducting phase-3 clinical trials of its Covid-19 vaccine candidate, has been asked to submit complete data of the ongoing phase-2 trial